Ribocure Pharmaceuticals
Ribocure Pharmaceuticals AB is a clinical-stage Swedish biotech and subsidiary of Suzhou Ribo Life Science (HKEX: 06938.HK) developing siRNA therapeutics using its proprietary RIBO-GalSTAR™ GalNAc liver-targeting platform. It out-licenses its cardiovascular, liver, and rare-disease pipeline to global pharmaceutical partners.
- Company typePrivate
- Founded2022
- HeadquartersMölndal, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ribocure Pharmaceuticals does
Ribocure Pharmaceuticals AB is a clinical-stage Swedish biotech founded in May 2022 and headquartered at GoCo Clinic in Mölndal, Sweden. It is a wholly-owned subsidiary of Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938.HK, listed January 2026) and functions as the parent's European R&D and clinical hub for siRNA-based oligonucleotide therapeutics. The company builds on the proprietary RIBO-GalSTAR™ platform, a GalNAc-conjugated liver-targeting delivery system that enables selective siRNA uptake in hepatocytes for gene silencing across cardiovascular, renal, liver, and rare-disease indications. Its pipeline includes vortosiran (RBD4059), the world's first siRNA targeting coagulation Factor XI (Phase 2/2b in VTE, SPAF, and CAD); RBD1119 for coronary artery disease; RBD1016 for chronic hepatitis B and D (with EMA Orphan Drug Designation in HDV); RBD5044 for hypertriglyceridemia and mixed dyslipidemia; RBD7007 for complement-mediated diseases; and R0797070 for hypertension.
Ribocure operates a vertically integrated "bench-to-bedside" model, co-locating R&D, an in vitro human cell lab, and the in-house Ribocure Clinic Phase 2 clinical trial unit with functional imaging core lab capacity, allowing it to run proof-of-concept trials in cardiovascular, pulmonary, renal, and liver indications. It employs 11–50 staff drawn heavily from AstraZeneca's Cardiovascular, Renal and Metabolism organization, including the CEO, CMO, CBO, and most department heads.
The company's revenue model is B2B and pre-commercial: income is generated through out-licensing and co-development agreements with pharmaceutical partners, primarily via upfront payments, development and commercial milestone payments, and tiered royalties. Its two anchor deals are with Boehringer Ingelheim (January 2024, NASH/MASH collaboration valued at over $2 billion in upfront, milestones, and royalties) and Madrigal Pharmaceuticals (February 2026, exclusive worldwide license to six preclinical MASH siRNA programs, $60 million upfront with up to $4.4 billion in potential milestone payments plus royalties). AI is embedded into discovery workflows via partnerships with Insilico Medicine and Pheiron. Customer segments are large pharmaceutical companies (licensing/co-development partners) and clinical research sites/healthcare providers for trial execution.
Ribocure Pharmaceuticals firmographics
Firmographics- Name
- Ribocure Pharmaceuticals
- Legal name
- Ribocure Pharmaceuticals AB
- Website
- https://ribocure.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ribocure Pharmaceuticals AB is a clinical-stage Swedish biotech and subsidiary of Suzhou Ribo Life Science (HKEX: 06938.HK) developing siRNA therapeutics using its proprietary RIBO-GalSTAR™ GalNAc liver-targeting platform. It out-licenses its cardiovascular, liver, and rare-disease pipeline to global pharmaceutical partners.
- Ownership category
- akta.pro rank
Ribocure Pharmaceuticals industry classification
Industry- Product category
- RNA Therapeutics / siRNA Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- siRNA Therapeutics (gene silencing) (HLAAADAB)
- akta.pro secondary industries
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI)
Keywords
Where Ribocure Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Mölndal
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Ribocure Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Distribution channels3 records
Marketing channels4 records
Ribocure Pharmaceuticals product offering
Product offeringCore offering
Ribocure Pharmaceuticals AB is a clinical-stage biotech company developing siRNA (small interfering RNA)-based oligonucleotide therapeutics for cardiovascular, renal, liver, and rare diseases, powered by its proprietary RIBO-GalSTAR™ GalNAc liver-targeting delivery platform. The company advances multiple drug candidates (including vortosiran/RBD4059, RBD1119, RBD1016, RBD5044, RBD7007, and an AGT siRNA) through clinical development and monetizes them primarily through licensing and co-development agreements with large pharmaceutical partners. An in-house Phase 2 clinical trial unit (Ribocure Clinic) supports proof-of-concept studies with functional imaging core lab capacity.
Product overview
Ribocure Pharmaceuticals is a clinical-stage biotech company developing cutting-edge siRNA (small interfering RNA) oligonucleotide therapeutics. The company's core portfolio includes multiple siRNA drug candidates targeting cardiovascular, metabolic, liver, and rare diseases. Key products include vortosiran (RBD4059) for FXI inhibition in thrombosis, RBD1119 for coronary artery disease, RBD1016 for hepatitis B/D, RBD5044 for hypertriglyceridemia, and RBD7007 for complement-mediated diseases. All programs leverage the proprietary RIBO-GalSTAR™ liver-targeting delivery platform. The company operates Ribocure Clinic, an in-house specialized Phase 2 clinical trial unit.
Differentiator
Problem solved
Functional benefit
Brands
- Ribocure Clinic: Specialized clinical trial unit within Ribocure Pharmaceuticals AB dedicated to Phase 2 proof-of-principle/concept trials with functional imaging core lab capacity, located at GoCo Clinic in Mölndal, Sweden.
Products and services
- vortosiran (RBD4059) World's first and most advanced GalNAc-conjugated siRNA drug targeting coagulation Factor XI (FXI). Achieves anti-thrombotic effects by suppressing FXI concentrations and inhibiting the intrinsic pathway of the coagulation cascade, offering durable antithrombotic protection with minimal bleeding risk. Being developed for multiple thrombotic indications including VTE, SPAF, and coronary artery disease.
- RBD1119 siRNA-based therapeutic targeting coronary artery disease (CAD), addressing residual thrombotic risk in stable CAD patients that standard antiplatelet and anticoagulant therapies fail to adequately manage while seeking to reduce bleeding risks.
- RBD1016 GalNAc-conjugated siRNA molecule targeting the X gene of hepatitis B virus. Inhibits all four HBV transcripts through RNA interference mechanism, reducing HBV DNA replication, cccDNA and HBsAg. Being developed for chronic hepatitis B infection and hepatitis D infection (HDV), the latter having received EMA Orphan Drug Designation in October 2025.
- RBD5044 GalNAc-siRNA conjugate targeting Apolipoprotein CIII (ApoC3) for hypertriglyceridemia and mixed dyslipidemia. Achieves long-lasting and efficient reduction of plasma triglycerides and ApoB-containing lipoproteins.
- RBD7007 GalNAc-conjugated siRNA targeting Complement Factor 5 (C5) mRNA in the liver. Being developed for complement-mediated diseases including Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA nephropathy, and Myasthenia Gravis (MG).
- R0797070 (AGT siRNA) GalNAc-siRNA molecule targeting liver angiotensinogen (AGT) for treatment of hypertension. Demonstrates sustained blood pressure reduction and improvement in left ventricular hypertrophy with best-in-class potential. Developed under the strategic collaboration with Boehringer Ingelheim.
- RIBO-GalSTAR™ Platform Proprietary liver-targeting siRNA delivery technology platform enabling selective uptake in hepatocytes for precise gene silencing. Powers Ribocure's siRNA therapeutic programs across cardiovascular, liver, and rare diseases via GalNAc conjugation.
- Ribocure Clinic Specialized Phase 2 clinical trial unit within GoCo Clinic for conducting proof-of-principle and concept trials. Features functional imaging core lab capacity and specializes in cardiovascular, pulmonary, renal, and liver disease areas with advanced imaging and functional assessments. Enables in-house clinical execution for Ribocure's siRNA pipeline.
Companies that use Ribocure Pharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
Ribocure Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Ribocure Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered supporting and core.
- Insilico MedicinesupportingAI-powered drug discovery collaboration leveraging Insilico's AI platforms for target identification and drug design in Ribocure's siRNA pipeline development.
- Madrigal PharmaceuticalscoreLicensing agreement for 6 preclinical siRNA programs targeting MASH (Metabolic dysfunction-Associated SteatoHepatitis). Deal includes $60 million upfront payment and up to $4.4 billion in potential milestone payments.
- Medtanken Group ABsupportingClinical trial collaboration with Medtanken Group AB for conducting clinical studies on siRNA therapeutic candidates in the Swedish healthcare system.
- PheironsupportingAI-assisted drug development partnership for optimizing siRNA therapeutic candidates using Pheiron's machine learning capabilities.
- Boehringer IngelheimcoreStrategic partnership for NASH/MASH therapies development. This is a major collaboration exceeding $2 billion in potential deal value, representing Ribocure's flagship partnership for liver disease therapeutics.
Recent moves8 records
Expansion highlights6 records
Ribocure Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Alnylam Pharmaceuticals: The pioneer and dominant commercial player in RNAi therapeutics, with approved GalNAc-conjugated siRNA drugs (Givlauri, Oxlumo) directly competing with Ribocure's liver-targeting siRNA platform and pipeline targets including cardiovascular and metabolic diseases.
- Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics developer with multiple liver-targeted candidates (TRiM platform) in cardiometabolic and MASH indications that directly overlap with Ribocure's RIBO-GalSTAR platform strategy and target portfolio.
- Silence Therapeutics: London-based clinical-stage siRNA company developing GalNAc-conjugated siRNA drugs for cardiovascular and hematological diseases (e.g., SLN360 targeting Lp(a)), competing head-to-head with Ribocure's RBD4059 and other GalNAc programs.
- Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company developing siRNA, ASO, and RNA editing programs. While Wave has a distinct PRISM platform, its cardiovascular and metabolic disease programs make it a direct comparable for RNA-targeted therapeutics in similar indications.
Broad incumbents
- Ionis Pharmaceuticals: The leading antisense oligonucleotide (ASO) company with deep cardiovascular and metabolic disease expertise (e.g., Waylivra, Tegsedi, Tryngolza). Competes with Ribocure for pharma partnership attention and cardiovascular indication targets, though using a different oligonucleotide modality.
- Dicerna Pharmaceuticals (Novo Nordisk): Acquired by Novo Nordisk for $3.3B in 2021, Dicerna developed GalXC RNAi platform technology with liver-targeting siRNAs. Now a wholly-owned subsidiary of Novo Nordisk, representing a fully integrated Big Pharma competitor in liver-targeted siRNA.
Emerging players
- Arbutus Biopharma: Clinical-stage HBV-focused biotech with GalNAc-conjugated siRNA (imdusiran) in chronic hepatitis B, directly comparable to Ribocure's RBD1016 program. Both target the same indication with RNAi-based approaches.
- ProQR Therapeutics: Clinical-stage RNA therapeutics company focused on rare diseases using Axiomer RNA editing technology. Adjacent modality (RNA editing vs siRNA) but targets similar rare disease indications and uses similar oligonucleotide delivery strategies.
- Vir Biotechnology: Clinical-stage immunology company with siRNA-based HBV/HDV programs (VIR-2218) that directly overlap with Ribocure's RBD1016 hepatitis B/D development efforts. Strong Big Pharma partnerships (Gilead, Alnylam) make it a credible competitor.
Others
- Insilico Medicine: AI-driven drug discovery company with Pharma.AI platform, partnered with Ribocure/Ribo (May 2026) for AI-assisted siRNA target identification and drug design. Not a direct competitor but a strategic enabler and ecosystem partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ribocure Pharmaceuticals social profiles
Digital presenceRibocure Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ribocure Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles15 records
Ribocure Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ribocure Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ribocure Pharmaceuticals
What does Ribocure Pharmaceuticals do?
Ribocure Pharmaceuticals AB is a clinical-stage biotech company developing siRNA (small interfering RNA)-based oligonucleotide therapeutics for cardiovascular, renal, liver, and rare diseases, powered by its proprietary RIBO-GalSTAR™ GalNAc liver-targeting delivery platform. The company advances multiple drug candidates (including vortosiran/RBD4059, RBD1119, RBD1016, RBD5044, RBD7007, and an AGT siRNA) through clinical development and monetizes them primarily through licensing and co-development agreements with large pharmaceutical partners. An in-house Phase 2 clinical trial unit (Ribocure Clinic) supports proof-of-concept studies with functional imaging core lab capacity.
Is Ribocure Pharmaceuticals a public or private company?
Ribocure Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Ribocure Pharmaceuticals founded?
Ribocure Pharmaceuticals was founded in 2022. It employs 11 to 50 people.
Where is Ribocure Pharmaceuticals based?
Ribocure Pharmaceuticals is headquartered in Mölndal, Sweden, in the Europe region.
Who are Ribocure Pharmaceuticals's main competitors?
Direct peers on record are Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics and Wave Life Sciences. Broad incumbents are Ionis Pharmaceuticals and Dicerna Pharmaceuticals (Novo Nordisk). Emerging players are Arbutus Biopharma, ProQR Therapeutics and Vir Biotechnology. Insilico Medicine is listed as an others.
Does Ribocure Pharmaceuticals have an API?
No public API is recorded for Ribocure Pharmaceuticals.
What industry is Ribocure Pharmaceuticals in?
Ribocure Pharmaceuticals's product category is RNA Therapeutics / siRNA Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.